CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...
Phase 3
Pittsburgh, Pennsylvania, United States and 59 other locations
and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple...
Phase 1
Pittsburgh, Pennsylvania, United States and 18 other locations
A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexa...
Phase 3
Pittsburgh, Pennsylvania, United States and 181 other locations
Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as in...
Phase 3
Pittsburgh, Pennsylvania, United States and 135 other locations
The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to ide...
Phase 1
Pittsburgh, Pennsylvania, United States and 26 other locations
The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to id...
Phase 1
Pittsburgh, Pennsylvania, United States and 30 other locations
maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple...
Phase 3
Pittsburgh, Pennsylvania, United States and 281 other locations
The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
Phase 2
Pittsburgh, Pennsylvania, United States and 47 other locations
The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal...
Phase 3
Pittsburgh, Pennsylvania, United States and 114 other locations
38 (CD38) treatment naive participants with newly diagnosed multiple myeloma who are MRD positive as determined by next generation...
Phase 3
Pittsburgh, Pennsylvania, United States and 72 other locations
Clinical trials
Research sites
Resources
Legal